» Drug Pipeline Free Press Releases

The coronary artery disease (CAD) market is a highly competitive market and is expected to become more competitive until 2016. Three major patent expiries are expected during the forecast period, Plavix and Lipitor by 2011 and Crestor by 2016. The patient expiries of these blockbuster drugs will

The coronary artery disease (CAD) market is a highly competitive market and is expected to become more competitive until 2016. Three major patent expiries are expected during the forecast period, Plavix and Lipitor by 2011 and Crestor by 2016. The patient expiries of these blockbuster drugs will

GlobalData predicts the AHF therapeutics market to be valued at $2.3 billion in 2009. The market is estimated to grow up to $2.6 billion in 2016, with a CAGR of 2.1%. Growth in the AHF market is driven by the increasing number of patients and the launch of new promising drugs during the next few

The CAD market is currently very competitive and is expected to get more competitive in the future. The market is expected to witness a decline between 2011 and 2013 due to the patent expiries of a few blockbuster drugs used in the treatment of CAD. The major drug patent expiries expected in the

GlobalData estimated that the Lyme disease market was worth $2.2m in 2009. The major reason for the limited market revenues is that there is no approved drug for Lyme disease treatment. Antibiotics such as doxycycline, cefuroxime and amoxicillin are currently used off-label. The patent protection

The global muscular dystrophy market was valued at $115m in 2009 and is forecast to grow by 3.8% annually for the next seven years to reach $150m in 2016. This increase is primarily due to the increase in the diagnosis rate that translated into an increased prescription rate. In addition, the

GlobalData’s analysis reveals that the Paget’s disease market was worth $159.2m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 8.9% for the next seven years and is expected to reach $82.3m by 2016. The negative growth rate is primarily attributable to a

The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in 2009 and is forecast to decline by 1% annually for the next seven years to reach $949m in 2016. This decline in market size is primarily due to the patent expirations of six branded drugs which will subsequently allow the

The atrial fibrillation (AF) market is currently on the brink of rapid expansion due to the expected launch of novel products between 2010 and 2016 with new first-in-class molecules likely to replace the age-old generics which have been dominating the market, chiefly due to their low costs and a

GlobalData estimated the Chronic Obstructive Pulmonary Disease (COPD) market to be worth $7.2 billion in 2009 and projects it to grow at a compound annual growth rate (CAGR) of 7.4% to reach $11.9 billion in 2016. The development of novel once-daily inhaled therapies is expected to provide new

GlobalData estimates that the global endometriosis market was valued at $1.7 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.3 billion by 2016. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market

GlobalData’s analysis suggests that the global venous thromboembolism (VTE) market was worth $1,535m in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 6.5% for the next seven years to reach $2,383m by 2016. This growth rate is primarily attributable to the strong